Beigene Ltd 6160-HK:Hong Kong Stock Exchange

*Data is delayed | HKD
Last | 05/20/22 CTT
85.30quote price arrow up+4.00 (+4.92%)
Volume
1,340,620
52 week range
73.80 - 278.60
Loading...
  • Open81.10
  • Day High85.30
  • Day Low80.70
  • Prev Close81.30
  • 52 Week High278.60
  • 52 Week High Date09/17/21
  • 52 Week Low73.80
  • 52 Week Low Date05/12/22

Key Stats

  • Market Cap13,603.26M
  • Shares Out1,334.8M
  • 10 Day Average Volume1.28M
  • Dividend-
  • Dividend Yield-
  • Beta0.4
  • YTD % Change-47.02

KEY STATS

  • Open81.10
  • Day High85.30
  • Day Low80.70
  • Prev Close81.30
  • 52 Week High278.60
  • 52 Week High Date09/17/21
  • 52 Week Low73.80
  • 52 Week Low Date05/12/22
  • Market Cap13,603.26M
  • Shares Out1,334.8M
  • 10 Day Average Volume1.28M
  • Dividend-
  • Dividend Yield-
  • Beta0.4
  • YTD % Change-47.02

RATIOS/PROFITABILITY

  • EPS (TTM)-9.07
  • P/E (TTM)-9.40
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Beigene Ltd

There is no recent news for this security.

Profile

MORE
BeiGene, Ltd. (BeiGene) is a global biotechnology company. The Company is focused on discovering, developing, manufacturing, and commercializing medicines to improve treatment outcomes and expand access for patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers, tislelizumab; an anti-PD-1 antibody immunotherapy for the...
John Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Xiaobin Wu Ph.D.
President, Chief Operating Officer, General Manager - China
Julia Wang
Chief Financial Officer
Address
Ke Xue Yuan Lu 30 Hao,Zhong Guan Cun
Sheng Ming Ke Xue Yuan, Chang Ping Qu
Grand Cayman, BEJ
KY1-1108
Cayman Islands